Interesting new science on CFS/ME
Posted , 6 users are following.
Brain Behav Immun. 2015 Sep 20. pii: S0889-1591(15)30020-9. doi: 10.1016/j.bbi.2015.09.013. [Epub ahead of print]Antibodies to ß adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome.Loebel M1, Grabowski P2, Heidecke H3, Bauer S2, Hanitsch LG2, Wittke K2, Meisel C4, Reinke P5, Volk HD6, Fluge Ø7, Mella O8, Scheibenbogen C6.Author information
Abstract
Infection-triggered disease onset, chronic immune activation and autonomic dysregulation in CFS point to an autoimmune disease directed against neurotransmitter receptors. Autoantibodies against G-protein coupled receptors were shown to play a pathogenic role in several autoimmune diseases. Here, serum samples from a patient cohort from Berlin (n= 268) and from Bergen with pre- and post-treatment samples from 25 patients treated within the KTS-2 rituximab trial were analysed for IgG against human α and ß adrenergic, muscarinic (M) 1-5 acetylcholine, dopamine, serotonin, angiotensin, and endothelin receptors by ELISA and compared to a healthy control cohort (n=108). Antibodies against ß2, M3 and M4 receptors were significantly elevated in CFS patients compared to controls. In contrast, levels of antibodies against α adrenergic, dopamine, serotonin, angiotensin, and endothelin receptors were not different between patients and controls. A high correlation was found between levels of autoantibodies and elevated IgG1-3 subclasses, but not with IgG4. Further patients with high ß2 antibodies had significantly more frequently activated HLA-DR+ T cells and more frequently thyreoperoxidase and anti-nuclear antibodies. In patients receiving rituximab maintenance treatment achieving prolonged B-cell depletion, elevated ß2 and M4 receptor autoantibodies significantly declined in clinical responder, but not in non-responder. We provide evidence that 29.5% of patients with CFS had elevated antibodies against one or more M acetylcholine and ß adrenergic receptors which are potential biomarkers for response to B-cell depleting therapy. The association of autoantibodies with immune markers suggests that they activate B and T cells expressing ß adrenergic and M acetylcholine receptors. Dysregulation of acetylcholine and adrenergic signalling could also explain various clinical symptoms of CFS.
Copyright © 2015. Published by Elsevier Inc.
PMID:
26399744
[PubMed - as supplied by publisher]
1 like, 9 replies
jcnps Ravenwood
Posted
Just think how useful we are - if we weren't ill so much progess wouldn't be being made in the science of the brain!
May not help us directly but hopefully the ones coming after us - my father died of a disease that is now treatable - thats progress and I'm sure the same will happen with this disease.
kind regards
Ravenwood jcnps
Posted
caitlin39841 Ravenwood
Posted
Ravenwood caitlin39841
Posted
Sassylass Ravenwood
Posted
Why don't you think this info wouldn't be of help to us soon? I'm not certain but out seems like this research could open up three treatment of CFS with a some types of drugs not previously used for CFS sufferers. If I'm understanding what I read somewhat correctly that is. I think this could be big news NOW.
Ravenwood Sassylass
Posted
I would like to believe that everything will go quickly, and we will get a cure soon. But, over time, I have lost my optimism. I try to be realistic without resorting to out and out pessimism. I hope that you are right and a cure will be right around the corner. I just don't want to get my hopes up and get them dashed once again. I hope you can understand that. Best wishes. Raven.
Sassylass Ravenwood
Posted
Ravenwood Sassylass
Posted
However, the research does suggest that scientists might be on the right path (finally), and may come up with what is wrong with us. And hopefully, come up with a treatment that doesn't include an IV and possible death.
Take care,
Raven
caitlin39841 Ravenwood
Posted
C